CDKN1A and B-cell chronic lymphocytic leukemia: In CLL patients with 13q deletions, this mechanism is altered with aconsequent reduction of CDKN1A, BBC3, and BCL2 expression (Cimmino et al., 2005;Fabbri et al., 2011).Moreover, miRNA expression profiles characterizing CLL phenotype have demonstrated thatdown-regulation of miR-223, miR-29c, miR-29b, and miR-181 families is strongly associatedwith disease progression in CLL cases harboring 17p deletion (Visone et al., 2009), while miR-21, miR- 92, miR-101, miR-150, miR-155,miR-146a, and miR-17-92 families are all highly expressed in B-CLL (Calin et al., 2004, 2005;Fulci et al., 2007).